Ipsen SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010259150
EUR
121.10
-0.4 (-0.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

70.39 k

Shareholding (Dec 2023)

FII

0.02%

Held by 3 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 20.88%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 41.05

 
3

Positive results in Jun 25

4

With ROE of 16.27%, it has a Fair valuation with a 2.32 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 10,351 Million ()

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.13%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

16.27%

stock-summary
Price to Book

2.45

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.76%
0%
1.76%
6 Months
16.33%
0%
16.33%
1 Year
11.1%
0%
11.1%
2 Years
19.31%
0%
19.31%
3 Years
20.74%
0%
20.74%
4 Years
32.41%
0%
32.41%
5 Years
76.4%
0%
76.4%

Ipsen SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.37%
EBIT Growth (5y)
8.12%
EBIT to Interest (avg)
41.05
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.76
Tax Ratio
17.35%
Dividend Payout Ratio
33.50%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
32.49%
ROE (avg)
20.88%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.32
EV to EBIT
7.71
EV to EBITDA
5.80
EV to Capital Employed
2.53
EV to Sales
2.60
PEG Ratio
0.33
Dividend Yield
1.19%
ROCE (Latest)
32.80%
ROE (Latest)
16.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Ipsen SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 3.39% vs 14.44% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 4.70% vs -6.19% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,127.50",
          "val2": "3,025.00",
          "chgp": "3.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "945.50",
          "val2": "1,128.20",
          "chgp": "-16.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "26.20",
          "val2": "23.80",
          "chgp": "10.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "162.00",
          "val2": "-233.60",
          "chgp": "169.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "619.90",
          "val2": "592.10",
          "chgp": "4.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "207.50%",
          "val2": "306.40%",
          "chgp": "-9.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
3,127.50
3,025.00
3.39%
Operating Profit (PBDIT) excl Other Income
945.50
1,128.20
-16.19%
Interest
26.20
23.80
10.08%
Exceptional Items
162.00
-233.60
169.35%
Consolidate Net Profit
619.90
592.10
4.70%
Operating Profit Margin (Excl OI)
207.50%
306.40%
-9.89%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 3.39% vs 14.44% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 4.70% vs -6.19% in Dec 2022

stock-summaryCompany CV
About Ipsen SA stock-summary
stock-summary
Ipsen SA
Pharmaceuticals & Biotechnology
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Coordinates stock-summary
Company Details
65 Quai Georges Gorse , BOULOGNE-BILLANCOURT None : 92100
stock-summary
Tel: 33 1 58335000
stock-summary
Registrar Details